News
Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty obligations to Apellis by 90% for Aspaveli® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback